STOCK TITAN

CEL-SCI Corp - CVM STOCK NEWS

Welcome to our dedicated page for CEL-SCI news (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on CEL-SCI stock.

CEL-SCI Corp (CVM) is a clinical-stage biotechnology leader advancing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. This page provides investors and researchers with timely updates on the company’s clinical trials, regulatory milestones, and strategic initiatives.

Access authoritative reporting on Multikine Phase 3 head and neck cancer trials, LEAPS platform developments, and collaborative research with institutions like the University of Georgia. Our curated news collection ensures you stay informed about material events influencing CEL-SCI’s scientific and operational trajectory.

Key updates include treatment efficacy data, FDA communications, intellectual property advancements, and partnership announcements. All content is rigorously verified to provide actionable insights for stakeholders monitoring immunotherapy innovations.

Bookmark this page for streamlined access to CEL-SCI’s latest developments. Check regularly for unbiased reporting on breakthroughs that shape the future of immune-based therapies.

Rhea-AI Summary
CEL-4000, a potential therapy for rheumatoid arthritis (RA), aims to rebalance the inflammatory response without compromising immune defense mechanisms. The article discusses the benefits of CEL-4000 compared to current RA treatments, emphasizing its potential to provide safe and effective therapy for RA patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
none
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) issues a letter to shareholders detailing successful advancements in the Multikine cancer therapy, presenting promising results from the Phase 3 trial. The company identified a target population for Multikine with significant survival benefits and presented key findings at a major oncology conference. The target population consists of newly diagnosed squamous cell carcinoma of the head and neck patients with specific characteristics, making them ideal candidates for Multikine treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.07%
Tags
none
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) reported financial results and key clinical & corporate developments for Multikine® in head and neck cancer patients. Recent data presented at ESMO Congress showed a 73% survival rate with Multikine vs 45% in control, with a 28% absolute survival benefit. Statistically significant results with no safety concerns. Target population identified for regulatory filings, estimated at 145,000 global patients annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
Rhea-AI Summary
CEL-SCI Corporation (CVM) closes a public offering of 3,875,000 shares of common stock at $2.00 per share, raising $7.75 million for continued development of Multikine* and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) announces a public offering of 3,875,000 shares of common stock at $2.00 per share, aiming to raise $7.75 million for further development of Multikine and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.68%
Tags
-
Rhea-AI Summary
CEL-SCI Corporation completes the commissioning of its Multikine manufacturing facility, a key step in preparing for regulatory approval for the treatment of head and neck cancer. The facility has been expanded and upgraded in anticipation of filing a Biologics License Application with the FDA and other regulators. This achievement signifies a significant milestone in bringing Multikine to market, and the company's CEO emphasizes the high value of their manufacturing trade secret, capability, and know-how.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.48%
Tags
none
Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) has received a product-specific waiver from the European Medicines Agency (EMA) Paediatric Committee, allowing them to commercialize their cancer immunotherapy Multikine in the European Union. This waiver is a significant step forward for the company, as it eliminates a major hurdle in their path towards commercialization in Europe. The waiver ensures that the company does not face delays in their plans for commercialization. The EU Paediatric Regulation, enacted in 2007, aims to strengthen the investigation and development of medicinal products for the pediatric population. This regulatory change has a direct impact on CEL-SCI's ability to bring Multikine to the market in Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
Rhea-AI Summary
CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2023, as well as key clinical and corporate developments. The company identified the target head and neck cancer patient population for Multikine, which saw a 73% survival rate vs 45% in the control at 5 years. The UK's National Institute for Health and Care Excellence (NICE) selected Multikine to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck. Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression. Financially, research and development expenses decreased by 11% and general and administrative expenses decreased by 16%. Net loss narrowed by 12% to approximately $32.2 million for the twelve months ended September 30, 2023 from $36.7 million in fiscal 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
-
Rhea-AI Summary
CEL-SCI Corporation (CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine to be evaluated as the potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the UK. NICE posted a detailed report from the UK’s National Institute for Health and Care Research (NIHR) regarding Multikine, its clinical data, and its potential to become a better standard of care in treating newly diagnosed head and neck cancer in the UK.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.27%
Tags
none
Rhea-AI Summary
CEL-SCI Corporation (CVM) Announces Closing of $5 Million Public Offering for Cancer Immunotherapy Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
CEL-SCI Corp

NYSE:CVM

CVM Rankings

CVM Stock Data

21.97M
82.27M
2.26%
8.78%
6.87%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
VIENNA